Medical Research
(H30)
990 on File
FOUNDATION FOR THE ACCREDITATION OF CELLULAR THERAPY
Financial strength (30%)
70/100
Reliability (20%)
55/100
Effectiveness (25%)
65/100
Impact (25%)
No data yet
CharityAI™ Score
Not yet evaluated
Financial Overview — FY 2024
$7.2M
Total Revenue
$6.3M
Total Expenses
$3.8M
Net Assets
35
Employees
Revenue Sources
Expense Breakdown
Program Expense Ratio
56.3%
Fundraising Efficiency
N/A
Operating Reserve
7.10x
Liability-to-Asset
0.0%
Revenue Diversification
92.9%
Compared with Peers
FY 2024
Compared with 332 similar organizations
(United States, Medical Research, $1M–$10M in expenses), FY 2024.
This organization
Middle half of peers (P25–P75)
Peer median
| Ratio | This org | Peer median | Position (P10 → P90) | |
|---|---|---|---|---|
|
Program expense ratio
Program expenses / total expenses
· higher is better
|
56.3% | 83.0% |
P10P90
|
Bottom quarter |
|
Admin expense ratio
Management and general / total expenses
· lower is better
|
43.8% | 10.7% |
P10P90
|
Bottom quarter |
|
Fundraising expense ratio
Fundraising expenses / total expenses
· lower is better
|
0.0% | 2.0% |
P10P90
|
Top quarter |
|
Operating reserve
Months of expenses covered by net assets
· higher is better
|
7.1 mo | 12.8 mo |
P10P90
|
Below median |
|
Liabilities to assets
Total liabilities / total assets
· lower is better
|
0.0% | 10.1% |
P10P90
|
Top quarter |
|
Revenue concentration
Share of revenue from the largest source
· lower is better
|
92.9% | 90.7% |
P10P90
|
Below median |
|
Revenue growth
Year over year revenue growth
|
31.1% | 12.5% |
P10P90
|
|
|
Expense growth
Year over year expense growth
|
27.8% | 11.1% |
P10P90
|
|
|
Surplus margin
Surplus as a share of revenue
|
11.7% | 2.9% |
P10P90
|
Financial History
| Year | Revenue | Expenses | Net Assets | Program % | Staff |
|---|---|---|---|---|---|
| 2024 | $7.2M | $6.3M | $3.8M | 56.3% | 35 |
| 2023 | $5.5M | $5.0M | $2.9M | 82.6% | 32 |
| 2022 | $4.7M | $4.4M | $2.4M | 65.8% | 24 |
| 2021 | $3.6M | $3.2M | N/A | — | 0 |
Donor Reviews
Write a ReviewNo reviews yet
Be the first to share your experience with this organization.